CorMedix (CRMD) has a market capitalization of approximately $623M, trading at $7.93 on the NASDAQ. Market cap moves with the live share price.
CorMedix's trailing twelve-month P/E ratio is 3.3x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
CorMedix runs a net profit margin of 45.2%, a gross margin of 85.8%, and an operating margin of 48.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
CorMedix reported revenue of
CorMedix does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
CorMedix carries a debt-to-equity ratio of 0.34x and a current ratio of 2.98x, with a market beta of 1.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CorMedix (CRMD) the key facts are: market cap $623M, P/E 3.3x, revenue
Get CorMedix's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.